stars 1 stars 2 stars 3

Founded in 2008, OncoGenesis is focused on addressing the tremendous, unmet clinical need for easy and accurate screening of women for cervical cancer. The company has developed a multiplex biomarker test that measures the critical cellular changes in a cervical tissue specimen. By measuring these markers, the test will be able to detect the presence of cervical cancer and precancerous high-grade lesions as well as the progression (staging), and aggressiveness of the disease.

OncoGenesis Questions

The OncoGenesis annual revenue was $5 million in 2026.

OncoGenesis is based in Salinas, California.

The NAICS codes for OncoGenesis are [541921, 541, 5419, 54192, 54].

The SIC codes for OncoGenesis are [722, 72].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users